DEM BioPharma

DEM BioPharma is a biotechnology startup focused on developing innovative immunotherapies for cancer treatment. The company's primary approach is to harness the power of the body's innate immune system, specifically macrophages and other myeloid effector cells, to eliminate tumors. This is achieved by targeting unique 'don't eat me' (DEM) and 'eat me' (EM) signals on cancer cells and macrophages. In simpler terms, the company is working on ways to make the body's immune system more effective at recognizing and destroying cancer cells.

The company's proprietary CHoMP™ platform is a key part of this process. This platform uses a technique called inter-cellular CRISPR screening to identify these DEM and EM signals in a systematic and unbiased way. Essentially, the platform helps the company to discover new ways to make the immune system more effective at fighting cancer.

DEM BioPharma's clients are primarily patients suffering from various types of cancer. The company operates in the biotechnology and healthcare markets, specifically within the field of immuno-oncology. Its business model revolves around the research, development, and eventual commercialization of its immunotherapies. The company generates revenue through the sale of these therapies once they have been approved for use.

The company was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik. The current Chief Scientific Officer, Dr. Christophe Quéva, joined in September 2022 and brings a wealth of experience from his previous roles at Oncorus Inc., iTeos Therapeutics, AstraZeneca, Amgen, and Gilead Sciences.

Keywords: Biotechnology, Immunotherapy, Cancer Treatment, Innate Immune System, Macrophages, Myeloid Effector Cells, 'Don't Eat Me' Signals, 'Eat Me' Signals, CHoMP™ Platform, Inter-cellular CRISPR Screening.